Skip to main content
Log in

Radionuclide therapy of malignant bone lesions

  • Letter to the Editor
  • Published:
European Journal of Nuclear Medicine and Molecular Imaging Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Florimonte L, Dellavedova L, Maffioli LS. Radium-223 dichloride in clinical practice: a review. Eur J Nucl Med Mol Imaging. 2016;43:1896–909.

    Article  CAS  PubMed  Google Scholar 

  2. Zlotta AR, Schulman CC. Can survival be prolonged for patients with hormone-resistant prostate cancer? Lancet. 2001;357:326–7. Commentary.

    Article  CAS  PubMed  Google Scholar 

  3. Deguchi T, Yang M, Ehara H, Ito S, Nishino Y, Takahashi Y, et al. Detection of micrometastatic prostate cancer cells in the bone marrow of patients with prostate cancer. Br J Cancer. 1997;75:634–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. US Food and Drug Administration. FDA Public Workshop on Clinical Trial Endpoints in Prostate Cancer, 21–22 June 2004. Silver Spring, MD: US Food and Drug Administration. http://www.fda.gov/ cancer drug approval endpoints

  5. Porter AT, McEwan AJ, Powe JE, Reid R, McGowan DG, Lukka H, et al. Results of a randomized phase-III trial to evaluate the efficacy of strontium-89 to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer. Int J Radiat Oncol Biol Phys. 1993;25:805–13.

    Article  CAS  PubMed  Google Scholar 

  6. Turner JH, Claringbold PG. A phase II study of treatment of painful multifocal skeletal metastases with single and repeated samarium-153 ethylenediaminetetramethylene phosphonate. Eur J Cancer. 1991;9:1084–6.

    Article  Google Scholar 

  7. Biersack HJ, Palmedo H, Andris A, Rogenhofer S, Knapp FF, Guhlke S, et al. Palliation and survival after repeated 188Re-HEDP therapy of hormone-refractory bone metastases of prostate cancer: a retrospective analysis. J Nucl Med. 2011;52:1721–6.

    Article  CAS  PubMed  Google Scholar 

  8. Kuroda I. Strontium-89 for prostate cancer with bone metastases: the potential of cancer control and improvement of overall survival. Ann Nucl Med. 2014;28:11–6.

    Article  CAS  PubMed  Google Scholar 

  9. Holmes RA. [153Sm]EDTMP: a potential therapy for bone cancer pain. Semin Nucl Med. 1992;22:41–5.

    Article  CAS  PubMed  Google Scholar 

  10. Collins C, Eary JF, Donaldson G, Vernon C, Bush NE, Petersdorf S, et al. Samarium-153-EDTMP in bone metastases of hormone refractory prostate cancer: a phase I/II trial. J Nucl Med. 1993;34:1839–44.

    CAS  PubMed  Google Scholar 

  11. Ricci S, Boni G, Pastina I, Genovesi D, Cianci C, Chiacchio S, et al. Clinical benefit of bone-targeted radiometabolic therapy with 153Sm-EDTMP combined with chemotherapy in patients with metastatic hormone-refractory prostate cancer. Eur J Nucl Med Mol Imaging. 2007;34:1023–30.

    Article  CAS  PubMed  Google Scholar 

  12. Maini CL, Bergomi S, Romano L, Sciuto R. 153Sm-EDTMP for bone pain palliation in skeletal metastases. Eur J Nucl Med Mol Imaging. 2004;31(1):171–8.

    Article  Google Scholar 

  13. Tu SM, Millikan RE, Mengistu B, Delpassand ES, Amato RJ, Pagliaro LC, et al. Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomised phase II trial. Lancet. 2001;357:336–41.

    Article  CAS  PubMed  Google Scholar 

  14. Sciuto R, Festa A, Rea S, Pasqualoni R, Bergomi S, Petrilli G, et al. Effects of low-dose cisplatin on 89Sr therapy for painful bone metastases from prostate cancer: a randomized clinical trial. J Nucl Med. 2002;43:79–86.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to M. Fischer.

Ethics declarations

Conflicts of interest

M.F. is a medical advisor to CIS bio GmbH Germany, responsible only for pharmacovigilance and medical information. He has received financial support to attend workshops and scientific meetings from Amgen, Bayer, GE Healthcare, IBA Molecular. H.J.B. is a senior advisor to Tasly (Hong Kong), Shanghai, China

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Fischer, M., Biersack, H.J. Radionuclide therapy of malignant bone lesions. Eur J Nucl Med Mol Imaging 44, 728–729 (2017). https://doi.org/10.1007/s00259-016-3574-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00259-016-3574-3

Keywords

Navigation